Physician profile
Cindy Bowen
NPI 1669646121
$1,141.64
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $210 · 2021: $11.56.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $221.89 | 2019-2021 | |
| Glaxosmithkline, LLC. | $199.04 | 2019 | |
| Philips North America LLC | $130.91 | 2019 | |
| Sunovion Pharmaceuticals INC. | $129.65 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $111.35 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.99 | 2019-2020 | |
| Genentech USA, INC. | $70.51 | 2019-2020 | |
| Advanced Respiratory, INC | $33.69 | 2020 | |
| Optinose US, INC. | $32.99 | 2019-2020 | |
| Mylan Specialty L.P. | $28.83 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $24.61 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.12 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.59 | 2020 | |
| Insmed, INC. | $14.47 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $12.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.